Mein Warenkorb

CD6

CD6 Molekülinformation

Englischer NameT-cell differentiation antigen CD6Anzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel1Target-AliasT12,CD6,CD6 Molecule,TP120,T-Cell Differentiation Antigen CD6,CD6 Antigen
Höchste Forschungs- und EntwicklungsphaseApproved
Englischer NameT-cell differentiation antigen CD6
Target-AliasT12,CD6,CD6 Molecule,TP120,T-Cell Differentiation Antigen CD6,CD6 Antigen
Anzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel1
Höchste Forschungs- und EntwicklungsphaseApproved

CD6 Produktliste

  • Attribut

    Protein (6)

  • Produktbibliothek

    Online (6)

  • Spezies

    Human (3)Cynomolgus (3)

  • Etikett

    His Tag (2)His Tag & Avi Tag (2)Fc Tag & Avi Tag (2)

  • Marker

    Unconjugated (2)Biotin-labeled (4)

CD6 Molekülhintergrund

CD6 (Cluster of Differentiation 6) is a cell surface glycoprotein that is involved in T cell activation and a member of the scavenger receptor cysteine rich protein superfamily (SRCRSF). CD6 is expressed at low levels on immature thymocytes and at high levels on mature thymocytes. The majority of peripheral blood T cells, a subset of B cells, and a subset of neuronal cells express CD6. CD6 appears to play a role as both a costimulatory molecule in T cell activation and as an adhesion receptor. Studies demonstrating a mitogenic effect for T cells with some CD6 specific monoclonal antibodies, in conjunction with either accessory cells or PMA and anti-CD2 mAb, support the concept of CD6 as a co stimulatory molecule.

CD6 Molekülalias

CD6,TP120,T12

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells therapy (City of Hope Medical Center)Phase 1 ClinicalCity Of Hope National Medical CenterDiabetes Mellitus, Type 1; Graft vs Host Disease; Hemic and Lymphatic Diseases
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
ItolizumabT-1-hT; EQ-001; T-1-h; h-T1; Bmab-600; Bmab600ApprovedCenter Of Molecular ImmunologyAlzumabIndiaPlaque psoriasisBiocon Ltd2013-01-01Asthma; Coronavirus Disease 2019 (COVID-19); Dermatomyositis; Graft vs Host Disease; Lupus Erythematosus, Cutaneous; Lupus Nephritis; Plaque psoriasis; Psoriasis; Respiratory Distress Syndrome, Adult
Details

Produktrezensionen

  • g***t2025-11-28
    0Menschen mögen
    We use Human CD16 from AcroBiosystems since many years now for in vitro characterization of antibodies and we are very happy to have well documented certificate to set up our experiments.
  • Molekülinformation
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Produktrezensionen
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns